Pso­ri­a­sis and pso­ri­at­ic arthri­tis drugs criss­cross cat­e­gories, but derm and rheum docs split on pref­er­ences

As drugs in pso­ri­a­sis and pso­ri­at­ic arthri­tis ther­a­py ar­eas nab new in­di­ca­tions that criss­cross the two cat­e­gories, der­ma­tol­o­gists and rheuma­tol­o­gists are as­sess­ing their op­tions. The twist? Emerg­ing opin­ions be­tween the two doc­tor groups are ex­act­ly the op­po­site, ac­cord­ing to Spher­ix Glob­al In­sights re­search analy­sis.

Rheuma­tol­o­gists “heav­i­ly” pre­fer In­ter­leukin 17s (IL-17s) such as No­var­tis’ Cosen­tyx and Eli Lil­ly’s Taltz to treat pso­ri­at­ic arthri­tis with on­ly 25% say­ing they pre­fer the In­ter­leukin 23s (IL-23s) that in­clude Janssen’s Trem­fya, Sun’s Ilumya and Ab­b­Vie’s Skyrizi. Mean­while, der­ma­tol­o­gists much pre­fer IL-23s, and es­pe­cial­ly Skyrizi, by about the same mar­gin, Spher­ix an­a­lysts said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER